VILDAGLIPTIN 50mg. IP

An anti-diabetic drug that reduces glycemia in patients with type 2 diabetes mellitus. (B Ahrén, 2011) Enhances pancreatic islet cell responsiveness to glucose. (Degrande, 2008) Improves the impaired sensitivity of the beta cells to glucose. (Foley, 2019) A well-tolerated and efficacious medicine in improving glycemic control in patients with type 2 diabetes mellitus. (Degrande, 2008) An effective therapy for glycemic control with a low risk of hypoglycemia. (L Cai, 2012) A safe and effective therapeutic option for patients with type 2 diabetes mellitus, both as monotherapy and as an add-on treatment. (Eleni Bekiari, 2016) A safe option for managing patients with type 2 diabetes mellitus. (Chantal Mathieu, 2017) An efficacious candidate in reducing glycosylated hemoglobin, fasting plasma glucose, and postprandial glucose levels. (Prato, 2007) An important choice for use in combination with metformin, a sulfonylurea, or a thiazolidinedione in patients with type 2 diabetes who require combination therapy. (Keating, 2010) An attractive therapeutic option in patients where metformin monotherapy alone is not sufficient. (Thomas Forst, 2014) More effective in decreasing HbA1c and enables patients to reach glycemic control than sitagliptin, and linagliptin. (Yun-Zhao Tang, 2015)